Free Trial
NASDAQ:VERA

Vera Therapeutics Q1 2024 Earnings Report

Vera Therapeutics logo
$19.25 -1.39 (-6.73%)
Closing price 04:00 PM Eastern
Extended Trading
$19.34 +0.09 (+0.44%)
As of 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Vera Therapeutics EPS Results

Actual EPS
-$0.56
Consensus EPS
-$0.53
Beat/Miss
Missed by -$0.03
One Year Ago EPS
N/A

Vera Therapeutics Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Vera Therapeutics Announcement Details

Quarter
Q1 2024
Time
Before Market Opens
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Vera Therapeutics' Q3 2025 earnings is scheduled for Wednesday, August 6, 2025

Vera Therapeutics Earnings Headlines

Vera (VERA) Q2 Net Loss Widens 127%
Wolfe Research Downgrades Vera Therapeutics (VERA)
Fed Decision Warning: How to Protect Your Wealth Before September 17th
On September 17th, the Fed faces an impossible choice—and Wall Street insiders are already preparing for the fallout. Whether Powell hikes or cuts, both paths lead to wealth destruction for unprepared investors. American Alternative Assets just released the Mar-A-Lago Accord, revealing how elites are positioning ahead of the decision—and how you can do the same.
See More Vera Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Vera Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Vera Therapeutics and other key companies, straight to your email.

About Vera Therapeutics

Vera Therapeutics (NASDAQ:VERA), a clinical stage biotechnology company, focuses on developing and commercializing treatments for patients with serious immunological diseases. Its lead product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection that is in Phase III clinical trial for patients with immunoglobulin A nephropathy; and for treatment of lupus nephritis that is in Phase II clinical trial. It is also developing MAU868, a human monoclonal antibody for the treatment of BK viremia infections. The company was formerly known as Trucode Gene Repair, Inc. and changed its name to Vera Therapeutics, Inc. in April 2020. Vera Therapeutics, Inc. was incorporated in 2016 and is headquartered in Brisbane, California.

View Vera Therapeutics Profile

More Earnings Resources from MarketBeat